TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1497039

Group type: EXPERIMENTAL
Intervention: Experimental group (larger dose increments of oxytocin)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Traditional group (standard dose increments of oxytocin)
Number of subjects: 151
Study: 6406448

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 60
Study: 30935341

Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 33

Group type: COMPARATOR
Intervention: Trigger point compression
Number of subjects: 33
Study: 29497121

Group type: EXPERIMENTAL
Intervention: Rupatadine 40 mg daily
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 27236887

Group type: EXPERIMENTAL
Intervention: Yiqi Fumai Lyophilized Powder (5.2 g in 500 mL normal saline)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Early goal-directed therapy (EGDT)
Number of subjects: 50
Study: 24567281

Group type: EXPERIMENTAL
Intervention: Self-expanding plastic stent (SEPS) placement
Number of subjects: 52
Study: 23479999

Group type: EXPERIMENTAL
Intervention: Furasidine potassium (furamag) 50 mg t.i.d. for 7 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Phosphomycin trometamol (monural) 3 g single dose for pulse therapy
Number of subjects: 60
Study: 20459883

Group type: EXPERIMENTAL
Intervention: Aripiprazole at 5‐15 mg/d
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 17609404

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily) for 6 months
Number of subjects: 50
Study: 15576654

Group type: EXPERIMENTAL
Intervention: RAS blockers (RASb) and acetylsalicylic acid (ASA)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Positive expression of NFkappaB
Number of subjects: 68
Study: 12167683

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 277

Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 277
Study: 10190876

Group type: EXPERIMENTAL
Intervention: Dipyridamole infusion
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: FCHL patients with phenotype IIB (n=8) during hyperemia
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: FCHL patients with phenotype IIB (n=8)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: FCHL patients
Number of subjects: 21

Group type: COMPARATOR
Intervention: Baseline MBF
Number of subjects: 21
Study: 7754886

Group type: EXPERIMENTAL
Intervention: Bowel cleansing with laxatives and allowed to eat (Group 1)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Bowel cleansing with laxatives and liquid supper followed by fasting (Group 2)
Number of subjects: 193

Group type: COMPARATOR
Intervention: No bowel cleansing and allowed to eat (Group 3)
Number of subjects: 193

Group type: COMPARATOR
Intervention: No bowel cleansing and liquid supper followed by fasting (Group 4)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Laxatives before examination (Groups 1 and 2 combined)
Number of subjects: 193

Group type: COMPARATOR
Intervention: No laxatives (Groups 3 and 4 combined)
Number of subjects: 193
Study: 2115298

Group type: EXPERIMENTAL
Intervention: Gestodene
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Number of subjects: 35
Study: 6986827

Group type: EXPERIMENTAL
Intervention: Azathioprine (2 mg/kg of body weight per day) with prednisone (60 mg per day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo with prednisone (60 mg per day)
Number of subjects: 16
Study: 31075401

Group type: EXPERIMENTAL
Intervention: Carbapenem group
Number of subjects: 101

Group type: COMPARATOR
Intervention: Alternative treatment group (cotrimoxazole 59.5%, quinolones 21.4%)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Alternative treatment group
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Carbapenem treatment
Number of subjects: 101
Study: 30716802

Group type: EXPERIMENTAL
Intervention: Medication plus voice therapy (Group B)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Medication alone (Group A)
Number of subjects: 71
Study: 26462480

Group type: EXPERIMENTAL
Intervention: IV ibandronate 1 mg/month
Number of subjects: 299

Group type: COMPARATOR
Intervention: Oral risedronate 2.5 mg/day
Number of subjects: 299
Study: 24856782

Group type: EXPERIMENTAL
Intervention: Aluminium hydroxide adjuvanted HNVAC vaccine
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Non-adjuvanted HNVAC vaccine
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study: 22114792

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (EPA 510 mg + DHA 340 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (850 mg)
Number of subjects: 33
Study: 19461257

Group type: EXPERIMENTAL
Intervention: Modular psychotherapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Enhanced community treatment
Number of subjects: 31
Study: 17257475

Group type: EXPERIMENTAL
Intervention: Disposable doser (InnoLet)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Vial/syringe
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Preference for disposable doser
Number of subjects: 260
Study: 15542043

Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) measurement using DXA
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Bone mineral content (BMC) measurement using DXA
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Apparent volumetric BMD (BMAD) calculation
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Comparison of BMD by socioeconomic status
Number of subjects: 363
Study: 11680399

Group type: EXPERIMENTAL
Intervention: Ropivacaine infiltration 1.5 mg/ml plus adrenaline 1/200,000 in normal saline 100 ml
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline 100 ml plus adrenaline 1/200,000
Number of subjects: 60
Study: 9626717

Group type: EXPERIMENTAL
Intervention: B-ERP
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: P-ERP
Number of subjects: 135

Group type: COMPARATOR
Intervention: RELAX
Number of subjects: 135
Study: 7946177

Group type: EXPERIMENTAL
Intervention: Sustained-release isradipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spirapril
Number of subjects: 0
Study: 3311191

Group type: EXPERIMENTAL
Intervention: Delayed administration of CyA following ATG treatment (group CyA)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional treatment including ATG (group STD)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Delayed administration of CyA
Number of subjects: 75
Study: 30227780

Group type: EXPERIMENTAL
Intervention: Short femoral stem
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Conventional femoral stem
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (66 subjects without hip pathology)
Number of subjects: 22
Study: 28994415

Group type: EXPERIMENTAL
Intervention: Peer health coaching (PHC)
Number of subjects: 42
Study: 26630050

Group type: EXPERIMENTAL
Intervention: Computer training tool only (Group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Remote-guidance only (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both RG and computer training tool (Group C)
Number of subjects: 0
Study: 25696967

Group type: EXPERIMENTAL
Intervention: remaxol
Number of subjects: 124

Group type: COMPARATOR
Intervention: basal therapy
Number of subjects: 124
Study: 21360528

Group type: EXPERIMENTAL
Intervention: Videoconference (VC) delivery of cognitive-behavioral anger management treatment (AMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-person delivery of cognitive-behavioral anger management treatment (AMT)
Number of subjects: 0
Study: 18460495

Group type: EXPERIMENTAL
Intervention: Low glycemic index (LGI) diet
Number of subjects: 11

Group type: COMPARATOR
Intervention: High glycemic index (HGI) diet
Number of subjects: 11
Study: 14552179

Group type: EXPERIMENTAL
Intervention: D‐panthenol (5% drops and 5% gel)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no D‐panthenol)
Number of subjects: 80
Study: 10468503

Group type: EXPERIMENTAL
Intervention: L‐N(G) methyl arginine hydrochloride (L‐NMMA) 6 mg/kg intravenous infusion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: L‐N(G) methyl arginine hydrochloride (L‐NMMA)
Number of subjects: 16
Study: 7782110

Group type: EXPERIMENTAL
Intervention: roxithromycin 150 mg b.i.d.
Number of subjects: 242

Group type: COMPARATOR
Intervention: amoxycillin 500 mg/clavulanic acid 125 mg t.i.d.
Number of subjects: 242
Study: 2212255

Group type: EXPERIMENTAL
Intervention: Intestinal decontamination (tobramycin 80 mg and colistin 100 mg, four times daily via gastric tube)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Intestinal decontamination
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 345985

Group type: EXPERIMENTAL
Intervention: IPPB
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Incentive spirometer
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Blow bottles
Number of subjects: 145
Study: 29996688

Group type: EXPERIMENTAL
Intervention: Extraperitoneal cesarean section
Number of subjects: 210

Group type: COMPARATOR
Intervention: Transperitoneal cesarean section
Number of subjects: 210
Study: 29781238

Group type: EXPERIMENTAL
Intervention: Venous Preservation Scan (VPS)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Routine Pre‐Operative Planning Scan (RPOPS)
Number of subjects: 123
Study: 27324882

Group type: EXPERIMENTAL
Intervention: Spa therapy plus standard drug treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard drug treatment alone
Number of subjects: 50
Study: 26354517

Group type: EXPERIMENTAL
Intervention: Unilateral right sacral nerve stimulation
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Unilateral left sacral nerve stimulation
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Bilateral sacral nerve stimulation
Number of subjects: 27
Study: 23489262

Group type: EXPERIMENTAL
Intervention: Instruction video about n‐ and u‐serrated patterns
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Instruction video about n‐ and u‐serrated patterns (UMCG group)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Instruction video about n‐ and u‐serrated patterns (International expert group)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Instruction video about n‐ and u‐serrated patterns (Blistering course group)
Number of subjects: 3
Study: 19789937

Group type: EXPERIMENTAL
Intervention: Diode laser treatment (810-nm, 2 W)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Hand instruments (control group)
Number of subjects: 18
Study: 19367427

Group type: EXPERIMENTAL
Intervention: Intensive nurse-led clinic
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard diabetes care
Number of subjects: 200
Study: 17693685

Group type: EXPERIMENTAL
Intervention: Dextrose (DEX)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Acid/alcohol-modified cornstarch (MAMS)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 7
Study: 15189092

Group type: EXPERIMENTAL
Intervention: Secretory phase (days 21 to 28 of the cycle)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Follicular phase (days 7 to 14 of the cycle)
Number of subjects: 7
Study: 11825173

Group type: EXPERIMENTAL
Intervention: SNOMED-RT
Number of subjects: 2022

Group type: COMPARATOR
Intervention: ICD9-CM
Number of subjects: 2022
Study: 9563139

Group type: EXPERIMENTAL
Intervention: 1-month depot (3.75 mg leuprorelin acetate)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 3-month depot (11.25 mg leuprorelin acetate)
Number of subjects: 42
Study: 7885968

Group type: EXPERIMENTAL
Intervention: Cefepime (1-2 g every 8-12 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 0
Study: 3199913

Group type: EXPERIMENTAL
Intervention: HBM clinical intervention
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: HBM telephone intervention
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Combination clinical/telephone interventions
Number of subjects: 842

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 842
Study: 31910819

Group type: COMPARATOR
Intervention: Nutritional intervention encouraging consumption of unprocessed and minimally processed foods and physical activities; three individualized nutritional counselling sessions.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 300
Study: 30947693

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2210
Study: 27686283

Group type: EXPERIMENTAL
Intervention: BioNet's aP vaccine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: BioNet's TdaP vaccine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Adacel® vaccine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All vaccine groups
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 60
Study: 26093979

Group type: EXPERIMENTAL
Intervention: mOPV1-1 week
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: mOPV1-2 weeks
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: mOPV1-4 weeks
Number of subjects: 1009

Group type: COMPARATOR
Intervention: bOPV-4 weeks
Number of subjects: 1009
Study: 23638799

Group type: EXPERIMENTAL
Intervention: High dairy (HD) - 4 servings of dairy per day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Low dairy (LD) - no more than 2 servings of dairy per day
Number of subjects: 23
Study: 20607595

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 80
Study: 19743978

Group type: COMPARATOR
Intervention: Paediatric feed (PF)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Adult feed (AF)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Older children's feed (OCF)
Number of subjects: 25
Study: 17606237

Group type: EXPERIMENTAL
Intervention: Reality TV cosmetic surgery program (The Swan)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Reality TV home improvement program (Clean Sweep)
Number of subjects: 147
Study: 14681341

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg single oral dose
Number of subjects: 23

Group type: COMPARATOR
Intervention: Etoricoxib in patients with advanced renal disease
Number of subjects: 23
Study: 11360159

Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Sibutramine after placebo (S/P)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo after Sibutramine (P/S)
Number of subjects: 44
Study: 10078796

Group type: EXPERIMENTAL
Intervention: Nurse-led follow-up care program
Number of subjects: 597

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 597
Study: 7917739

Group type: EXPERIMENTAL
Intervention: Ornipressin 10(‐4) u. ml‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ornipressin 10(‐2) u. ml‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ornipressin 10(‐1) u. ml‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ornipressin 10(0) u. ml‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ornipressin 10(‐3) to 10(‐1) u. ml‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ornipressin (various concentrations)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Plain 0.9% saline
Number of subjects: 30
Study: 3293456

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (80 mg/kg each Monday and Thursday during external radiation therapy)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Misonidazole (1 gm/m2 in the same schedule, not to exceed 12 gm/m2)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 296

Group type: COMPARATOR
Intervention: Misonidazole
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 296
Study: 31832749

Group type: EXPERIMENTAL
Intervention: Bronchoscopic lung volume reduction (BLVR) procedures (valves, coils, thermal vapor ablation)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Not applicable (control group of patients not eligible for BLVR)
Number of subjects: 138
Study: 29696684

Group type: EXPERIMENTAL
Intervention: Fostamatinib (100 mg BID for 24 weeks, increased to 150 mg BID for nonresponders after 4 weeks)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fostamatinib
Number of subjects: 150
Study: 28741744

Group type: EXPERIMENTAL
Intervention: Thermal Suit (T‐Balance®)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional cotton clothes (Control)
Number of subjects: 100
Study: 26653203

Group type: EXPERIMENTAL
Intervention: Self-testing (4 oral-fluid self-test kits at enrolment, additional kits on request)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Self-testing
Number of subjects: 350

Group type: COMPARATOR
Intervention: Standard-care (routine clinic-based testing)
Number of subjects: 350
Study: 24023320

Group type: EXPERIMENTAL
Intervention: 2,000 IU vitamin D‐3
Number of subjects: 36
Study: 21435332

Group type: EXPERIMENTAL
Intervention: Exposure + Response Prevention (no safety behaviours)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Exposure + Safety Behaviours (cleaning hands with a hygienic wipe)
Number of subjects: 44

Group type: COMPARATOR
Intervention: No-Intervention Control Group
Number of subjects: 44
Study: 18192839

Group type: EXPERIMENTAL
Intervention: ACEIs (Angiotensin-Converting Enzyme Inhibitors) administered for 6 weeks
Number of subjects: 509
Study: 16704648

Group type: EXPERIMENTAL
Intervention: Two-compound product (Dovobet/Daivobet/Taclonex) for 52 weeks
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Alternating group (two-compound product and calcipotriol for 52 weeks)
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Calcipotriol for 48 weeks after 4 weeks of the two-compound product
Number of subjects: 634

Group type: COMPARATOR
Intervention: Two-compound product vs Calcipotriol
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Two-compound product
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Alternating group
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Calcipotriol group
Number of subjects: 634
Study: 15581966

Group type: EXPERIMENTAL
Intervention: High-dose intraarterial infusion chemotherapy under percutaneous pelvic perfusion with extracorporeal chemofiltration (PPPEC) using high-dose cisplatin alone (140-250 mg/m2) or high-dose cisplatin plus mitomycin C (7 mg/m2), pepleomycin (7 mg/m2) and 5-fluorouracil (700 mg/m2)
Number of subjects: 23
Study: 10945313

Group type: EXPERIMENTAL
Intervention: Grapefruit juice with 5 mg felodipine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Grapefruit juice with 2.5 mg felodipine for 2 days followed by 5 mg felodipine for 6 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water with 5 mg felodipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water with 2.5 mg felodipine for 2 days followed by 5 mg felodipine for 6 days
Number of subjects: 12
Study: 9323507

Group type: EXPERIMENTAL
Intervention: CWB: continuous warm blood cardioplegia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ICB: intermittent cold blood with warm blood controlled reperfusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cryst: intermittent cold crystalloid cardioplegia
Number of subjects: 60
Study: 8405008

Group type: EXPERIMENTAL
Intervention: Pravastatin 5 mg/day (Group 1)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/day (Group 2)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combined therapy (both groups)
Number of subjects: 34
Study: 3633503

Group type: EXPERIMENTAL
Intervention: Therapeutic touch (TT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo simulation of TT
Number of subjects: 60
Study: 30219475

Group type: EXPERIMENTAL
Intervention: Hydroalcoholic extract of M. officinalis (HEMO) (700 mg/d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Hydroalcoholic extract of M. officinalis (HEMO)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 25747955

Group type: EXPERIMENTAL
Intervention: 1000 mg omega-3 fatty acid supplements (containing 180 mg eicosapentaenoic acid and 120 mg docosahexanoic acid)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 25517587

Group type: EXPERIMENTAL
Intervention: Motivational reinforcement by researchers and technical staff members
Number of subjects: 60

Group type: COMPARATOR
Intervention: No motivational reinforcement
Number of subjects: 60
Study: 22813682

Group type: EXPERIMENTAL
Intervention: GWL+SWA
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: GWL
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: SWA
Number of subjects: 197

Group type: COMPARATOR
Intervention: SC
Number of subjects: 197
Study: 20063120

Group type: EXPERIMENTAL
Intervention: Bevacizumab + chemotherapy
Number of subjects: 3163

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 3163
Study: 18710420

Group type: EXPERIMENTAL
Intervention: Xylometazoline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16396000

Group type: EXPERIMENTAL
Intervention: Nonparametric approach to assess noninferiority
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parametric or semiparametric methods
Number of subjects: 0
Study: 14622039

Group type: EXPERIMENTAL
Intervention: Respect Not Risk Firearm Safety Lesson
Number of subjects: 433
Study: 10942228

Group type: EXPERIMENTAL
Intervention: Low-dose cytarabine (LDAC), 10 mg/m2 subcutaneously twice a day for 21 days every 2 months until relapse.
Number of subjects: 86

Group type: COMPARATOR
Intervention: Observation (no additional therapy).
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Low-dose cytarabine (LDAC).
Number of subjects: 86
Study: 8932271

Group type: EXPERIMENTAL
Intervention: Fully matched for 17 DRB1 specificities
Number of subjects: 74

Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Matched group (fully compatible)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Mismatched group
Number of subjects: 74
Study: 1578935

Group type: EXPERIMENTAL
Intervention: Allogeneic BMT
Number of subjects: 96

Group type: COMPARATOR
Intervention: Autologous BMT
Number of subjects: 96

Group type: COMPARATOR
Intervention: Prolonged intensive chemotherapy
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Early intensification (HDAra-C+amsacrine or IDAra-C+mitoxantrone followed by vincristine+adriamycin+cyclophosphamide and etoposide+Ara-C)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Overall disease-free survival (DFS)
Number of subjects: 96